Coherus BioSciences (CHRS) – Analyst EPS View
-
Coherus Biosciences (CHRS) PT Lowered to $38 at BMO Capital; 'Refiling of Neulasta Biosimilar Remains on Track for 4Q17'
-
Coherus Biosciences (CHRS) PT Lowered to $24 at Credit Suisse; Neulasta Biosimilar CRL Poses Greater Risk for CHS-1701
-
-
-
Back to CHRS Stock Lookup